Robertson Katharine A, Volmink Jimmy A, Mayosi Bongani M
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
BMC Cardiovasc Disord. 2005 May 31;5(1):11. doi: 10.1186/1471-2261-5-11.
Rheumatic fever continues to put a significant burden on the health of low socio-economic populations in low and middle-income countries despite the near disappearance of the disease in the developed world over the past century. Antibiotics have long been thought of as an effective method for preventing the onset of acute rheumatic fever following a Group-A streptococcal (GAS) throat infection; however, their use has not been widely adopted in developing countries for the treatment of sore throats. We have used the tools of systematic review and meta-analysis to quantify the effectiveness of antibiotic treatment for sore throat, with symptoms suggestive of group A streptococcal (GAS) infection, for the primary prevention of acute rheumatic fever.
Trials were identified through a systematic search of titles and abstracts found in the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 4, 2003), MEDLINE (1966-2003), EMBASE (1966-2003), and the reference lists of identified studies. The selection criteria included randomised or quasi-randomised controlled trials comparing the effectiveness of antibiotics versus no antibiotics for the prevention of rheumatic fever in patients presenting with a sore throat, with or without confirmation of GAS infection, and no history of rheumatic fever.
Ten trials (n = 7665) were eligible for inclusion in this review. The methodological quality of the studies, in general, was poor. All of the included trials were conducted during the period of 1950 and 1961 and in 8 of the 10 trials the study population consisted of young adult males living on United States military bases. Fixed effects, meta-analysis revealed an overall protective effect for the use of antibiotics against acute rheumatic fever of 70% (RR = 0.32; 95% CI = 0.21-0.48). The absolute risk reduction was 1.67% with an NNT of 53. When meta-analysis was restricted to include only trials evaluating penicillin, a protective effect of 80% was found (Fixed effect RR = 0.20, 95% CI = 0.11-0.36) with an NNT of 60. The marginal cost of preventing one case of rheumatic fever by a single intramuscular injection of penicillin is approximately USD 46 in South Africa.
Antibiotics appear to be effective in reducing the incidence of acute rheumatic fever following an episode of suspected GAS pharyngitis. This effect may be achieved at relatively low cost if a single intramuscular penicillin injection is administered.
尽管在过去一个世纪里,风湿热在发达国家几乎消失,但它仍继续给低收入和中等收入国家社会经济地位低下人群的健康带来沉重负担。长期以来,抗生素一直被认为是预防A组链球菌(GAS)咽喉感染后急性风湿热发作的有效方法;然而,在发展中国家,抗生素尚未广泛用于治疗咽喉痛。我们运用系统评价和荟萃分析工具,对疑似A组链球菌(GAS)感染症状的咽喉痛采用抗生素治疗对急性风湿热一级预防的有效性进行了量化。
通过系统检索Cochrane对照试验中心注册库(2003年第4期Cochrane图书馆)、MEDLINE(1966 - 2003年)、EMBASE(1966 - 2003年)中找到的标题和摘要以及已识别研究的参考文献列表来确定试验。选择标准包括随机或半随机对照试验,比较抗生素与不使用抗生素对出现咽喉痛(无论是否确诊GAS感染)且无风湿热病史患者预防风湿热的有效性。
10项试验(n = 7665)符合纳入本综述的条件。总体而言,这些研究的方法学质量较差。所有纳入试验均在1950年至1961年期间进行,10项试验中有8项的研究人群为居住在美国军事基地的年轻成年男性。固定效应荟萃分析显示,使用抗生素预防急性风湿热的总体保护效果为70%(RR = 0.32;95%CI = 0.21 - 0.48)。绝对风险降低率为1.67%,需治疗人数为53。当荟萃分析仅限于评估青霉素的试验时,发现保护效果为80%(固定效应RR = 0.20,95%CI = 0.11 - 0.36),需治疗人数为60。在南非,单次肌肉注射青霉素预防一例风湿热的边际成本约为46美元。
抗生素似乎能有效降低疑似GAS咽炎发作后急性风湿热的发病率。如果单次肌肉注射青霉素,可能以相对较低的成本实现这一效果。